Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Cannabidiol  COVID-19 treatment studies for Cannabidiol  C19 studies: Cannabidiol  Cannabidiol   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case -212% Improvement Relative Risk Symptomatic case (b) -71% Case -3% Merianos et al. Cannabidiol for COVID-19 Prophylaxis Favors cannabidiol Favors control
Concurrent use of e-cigarettes and cannabis and associated COVID-19 symptoms, testing, and diagnosis among student e-cigarette users at four U.S. Universities
Merianos et al., Addictive Behaviors, doi:10.1016/j.addbeh.2021.107170
Merianos et al., Concurrent use of e-cigarettes and cannabis and associated COVID-19 symptoms, testing, and diagnosis among.., Addictive Behaviors, doi:10.1016/j.addbeh.2021.107170
Mar 2022   Source   PDF  
  All Studies   Meta
Retrospective 800 e-cigarette users in the USA, showing higher risk of COVID-19 diagnosis and symptoms with cannabis use.
risk of symptomatic case, 211.9% higher, RR 3.12, p < 0.001, treatment 94 of 416 (22.6%), control 20 of 384 (5.2%), odds ratio converted to relative risk, COVID-19 symptoms.
risk of symptomatic case, 70.6% higher, RR 1.71, p = 0.008, treatment 77 of 416 (18.5%), control 38 of 384 (9.9%), odds ratio converted to relative risk, COVID-19 diagnosis.
risk of case, 3.4% higher, RR 1.03, p = 0.33, treatment 367 of 416 (88.2%), control 317 of 384 (82.6%), odds ratio converted to relative risk, COVID-19 test.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Merianos et al., 31 Mar 2022, retrospective, USA, peer-reviewed, survey, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Abstract: Addictive Behaviors 126 (2022) 107170 Contents lists available at ScienceDirect Addictive Behaviors journal homepage: Concurrent use of e-cigarettes and cannabis and associated COVID-19 symptoms, testing, and diagnosis among student e-cigarette users at four U. S. Universities Ashley L. Merianos a, *, Alex M. Russell b, E. Melinda Mahabee-Gittens c, Adam E. Barry d, Meng Yang e, Hsien-Chang Lin e a School of Human Services, University of Cincinnati, Cincinnati, OH, USA Department of Health, Human Performance, & Recreation, University of Arkansas, 308 HPER Building, Fayetteville, AR 72703, USA c Division of Emergency Medicine, Cincinnati Children’s Hospital Medical Center, College of Medicine, University of Cincinnati, Cincinnati, OH 45229, USA d Department of Health and Kinesiology, Texas A&M University, College Station, TX 77843-4243, USA e Department of Applied Health Science, Indiana University School of Public Health - Bloomington, Bloomington, IN, 47405, USA b A R T I C L E I N F O A B S T R A C T Keywords: Electronic nicotine delivery systems Cannabis use College students Introduction: This investigation assessed whether current (past 30-day) electronic cigarette (e-cigarette) and cannabis use was associated with coronavirus disease 2019 (COVID-19) symptomatology, testing, and diagnosis among college student e-cigarette users. Methods: Participants were 18–26-year-old college student e-cigarette users attending four geographically diverse, large U.S. public universities during October-December 2020 (N = 800). Multivariable logistic regres­ sion models explored associations between exclusive e-cigarette use and concurrent e-cigarette and cannabis use and COVID-19 symptoms, testing, and diagnosis. Models controlled for demographics, university site, and cur­ rent use of combustible cigarettes, cigars, and smokeless tobacco. Results: Over half of student e-cigarette users (52.0%) concurrently used cannabis. Compared to exclusive ecigarette users, concurrent e-cigarette and cannabis users were 3.53 times more likely (95%CI = 1.96–6.36) to report COVID-19 symptoms, after adjusting for the covariates. Compared to infrequent exclusive e-cigarette users, infrequent concurrent users (AOR = 4.72, 95%CI = 1.31–17.00), intermediate concurrent users (AOR = 5.10, 95%CI = 1.37–18.97), and frequent concurrent users (AOR = 7.44, 95%CI = 2.06–26.84) were at increased odds of reporting COVID-19 symptoms. Compared to exclusive e-cigarette users, concurrent e-cigarette and cannabis users were 1.85 times more likely (95%CI = 1.15–2.98) to report a COVID-19 diagnosis. Intermediate concurrent users (AOR = 2.88, 95%CI = 1.13–7.35) and frequent concurrent users (AOR = 3.22, 95%CI = 1.32–7.87) were at increased odds of reporting a COVID-19 diagnosis, compared to infrequent exclusive ecigarette users. Conclusions: Concurrent use of e-cigarettes and cannabis may be an underlying risk factor of COVID-19 symp­ tomatology and diagnosis, with more pronounced odds found among intermediate and frequent users. Results highlight the need to educate students about the impacts of e-cigarette and cannabis use on respiratory, immune, and overall health.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop